Precision Therapeutics plans to launch Med BioGene's LungExpress Dx molecular diagnostic by mid-year, the companies announced this week.
Precision Therapeutics Assesses Multi-Gene Predictors of Breast Cancer Chemo Response
NEW YORK (GenomeWeb News) – Rosetta Genomics announced after the close of the market on Tuesday that it has revised its co-marketing deal with Precision Therapeutics.
NEW YORK (GenomeWeb News) – Med BioGene today announced it has amended its commercialization agreement with Precision Therapeutics for Med Bio's LungExpress Dx test.
NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a deal with Precision Therapeutics to co-market Rosetta's miRview mets2 assay.
Precision Therapeutics' BioSpeciFx
Med BioGene's shareholders have approved the deal, which gives Precision rights to commercialize Med BioGene's gene expression-based test for early stage non-small-cell lung cancer.
Precision Therapeutics made an improved offer, matching the upfront payment offered by Signal Genetics to license the LungExpress Dx technology.
The new offer comes a month after Signal filed suit against Med BioGene for negotiating a licensing deal for the LungExpress Dx test with Precision Therapeutics.
Precision Therapeutics has gained exclusive rights to the LungExpress Dx test.
Researchers are sampling the wild relatives of modern crops to try to preserve genetic diversity, NPR reports.
Undark reports on a bill introduced this year to the US House of Representatives to strengthen scientific integrity.
MIT's Search for Extraterrestrial Genomes is developing sequencing tools to use to try to detect whether there is any life on Mars, Quartz reports.
In Genome Research this week: post-zygotic mutations in diabetes development, single-cell RNA sequencing study of aging, and more.